Department of Gynecology and Obstetrics, Agaplesion Markus Hospital, Germany.
Breast Cancer Center, Hospital Essen Mitte, Germany.
Breast. 2014 Feb;23(1):94-6. doi: 10.1016/j.breast.2013.11.002. Epub 2013 Dec 2.
The goal in breast conserving surgery (BCS) of ductal carcinoma in situ (DCIS) is removal of the tumor with a clear surgical margin. However, re-excision rates are regrettably high. To date, there are no adequate procedures for intraoperative margin assessment of DCIS. A multicenter, single arm study was conducted to evaluate the benefit of a novel device (MarginProbe®) in intraoperative margin assessment during BCS of DCIS, the associated reduction of re-excisions and the cosmetic outcome of the treated patients. We present results of 42 patients enrolled in 3 German institutions. The device was used as an adjunctive tool to standard of care. The device use was associated with a reduction in re-excision rates by 56%, from 39% to 17% (p = 0.018).
保乳手术（BCS）治疗导管原位癌（DCIS）的目标是在保证切缘阴性的情况下彻底切除肿瘤。但遗憾的是，该术式的局部复发率仍较高。目前，针对 DCIS 术中切缘评估尚无明确有效的方法。本研究旨在评估 MarginProbe®在 DCIS 保乳术中评估切缘的有效性，及其降低局部复发率和改善美容效果的作用。该多中心、单臂研究共纳入了 3 家德国医疗机构的 42 名患者。该设备作为标准治疗的辅助工具使用。结果显示，与标准治疗相比，该设备可使局部复发率降低 56%，从 39%降至 17%（p = 0.018）。
